{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:47:38Z","timestamp":1788562058647,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.urolonc.2020.06.013","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T01:13:06Z","timestamp":1594343586000},"page":"774-782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review"],"prefix":"10.1016","volume":"38","author":[{"given":"Keiichiro","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Babjuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Mostafaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Quhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza Sari","family":"Motlagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.06.013_bib0001","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0002","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) \u2013 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0003","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1464-410X.2010.09628.x","article-title":"Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort","volume":"107","author":"Svatek","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0004","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0005","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/bjc.2013.372","article-title":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder","volume":"109","author":"Xylinas","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0006","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1002\/cncr.26198","article-title":"Compliance with guidelines for patients with bladder cancer: variation in the delivery of care","volume":"117","author":"Chamie","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0007","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.juro.2008.04.016","article-title":"Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project","volume":"180","author":"Huang","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0008","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/cncr.26402","article-title":"Quality of care in patients with bladder cancer: a case report?","volume":"118","author":"Chamie","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0010","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0011","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0012","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s11255-018-1863-4","article-title":"A care bundle to improve perioperative mitomycin use in non-muscle-invasive bladder cancer","volume":"50","author":"Batura","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0013","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.juro.2012.08.044","article-title":"Understanding the use of immediate intravesical chemotherapy for patients with bladder cancer","volume":"188","author":"Burks","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0014","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s00345-019-02697-8","article-title":"Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC)","volume":"37","author":"Datovo","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000321926","article-title":"Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study","volume":"86","author":"Gontero","year":"2011","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0016","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5489\/cuaj.3143","article-title":"Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta","volume":"10","author":"Gotto","year":"2016","journal-title":"J Can Urol Assoc"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0017","first-page":"245","article-title":"Non-muscle invasive bladder cancer: are epicrises the 'Bermuda Triangle' of information transfer?","volume":"70","author":"Lebentrau","year":"2017","journal-title":"Cent Eur J Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0018","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00345-018-2199-5","article-title":"The effects of intra-arterial chemotherapy on bladder preservation in patients with T1 stage bladder cancer","volume":"36","author":"Liu","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0019","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.urpr.2015.10.003","article-title":"Guideline adherence of immediate post-transurethral resection intravesical chemotherapy for patients with nonmuscle invasive bladder cancer","volume":"3","author":"Matsumoto","year":"2016","journal-title":"Urol Pract"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000443705","article-title":"Impact of adjuvant intravesical bacillus Calmette-Gu\u00e9rin treatment on patients with high-grade T1 bladder cancer","volume":"96","author":"Novotny","year":"2016","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0021","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4149\/neo_2018_170217N123","article-title":"Predictors and prognostic implications of clinical decisions in patients with primary high-risk non-muscle-invasive bladder cancer \u2013 results of a cross country retrospective study","volume":"65","author":"Poletajew","year":"2018","journal-title":"Neoplasma"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0022","doi-asserted-by":"crossref","first-page":"8.e17","DOI":"10.1016\/j.urolonc.2017.08.027","article-title":"Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer","volume":"36","author":"Rieken","year":"2018","journal-title":"Urol Oncol: Semin Original Invest"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0023","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1445-2197.2011.05894.x","article-title":"Challenges in non-muscle invasive bladder cancer: lessons from a regional review","volume":"81","author":"Siddins","year":"2011","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0024","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000493369","article-title":"Evaluating guideline adherence for T1 bladder cancer treatment and surveillance: a retrospective german multicenter observation","volume":"101","author":"Vetterlein","year":"2018","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0025","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bju.12012","article-title":"Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guerin (BCG): results of an international individual patient data survey (IPDS)","volume":"112","author":"Witjes","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0026","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0027","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eururo.2013.06.009","article-title":"Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review","volume":"64","author":"Perlis","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0028","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1464-410X.2009.08654.x","article-title":"Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection?","volume":"104","author":"Dobruch","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0029","doi-asserted-by":"crossref","first-page":"45479","DOI":"10.18632\/oncotarget.9991","article-title":"Single, immediate postoperative instillation of chemotherapy in non-muscle invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials using different drugs","volume":"7","author":"Kang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0030","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events","volume":"7","author":"Witjes","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0031","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.eursup.2010.08.005","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin: the standard of care for the prophylaxis and management of intermediate- and high-risk non\u2013muscle-invasive bladder cancer","volume":"9","author":"Lamm","year":"2010","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0032","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MOU.0000000000000544","article-title":"What to do during bacillus Calmette-Guerin shortage? Valid strategies based on evidence","volume":"28","author":"Abufaraj","year":"2018","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0033","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MOU.0000000000000739","article-title":"Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the bacillus Calmette-Guerin shortage","volume":"30","author":"Fankhauser","year":"2020","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0034","article-title":"Recurrence rate and cost consequence of the shortage of bacillus Calmette-Guerin connaught strain for bladder cancer patients","volume":"S2405-4569","author":"Ourfali","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0035","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJMp1615697","article-title":"Ensuring access to injectable generic drugs \u2013 the case of intravesical BCG for bladder cancer","volume":"376","author":"Davies","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0036","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","article-title":"Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort","volume":"57","author":"Fritsche","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0037","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0022-5347(05)01002-5","article-title":"The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial","volume":"175","author":"Divrik","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0038","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.juro.2013.08.022","article-title":"The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guerin","volume":"191","author":"Sfakianos","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0039","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0040","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.euf.2017.09.002","article-title":"Discrepancy between European Association of Urology guidelines and daily practice in the management of non-muscle-invasive bladder cancer: results of a European survey","volume":"5","author":"Hendricksen","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0041","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0042","doi-asserted-by":"crossref","first-page":"E284","DOI":"10.1111\/j.1464-410X.2010.09980.x","article-title":"Early vs delayed radical cystectomy for 'high-risk' carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival","volume":"108","author":"Jager","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0043","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0022-5347(05)00423-4","article-title":"The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma","volume":"175","author":"Kamat","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0044","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0045","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/j.clgc.2019.01.007","article-title":"Determinants of guideline-based treatment in patients with cT1 bladder cancer","volume":"17","author":"Balakrishnan","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0046","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11934-019-0952-y","article-title":"Current clinical trials in non-muscle-invasive bladder cancer: heightened need in an era of chronic BCG shortage","volume":"20","author":"Packiam","year":"2019","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0047","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Fut Oncol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0048","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2019.37.7_suppl.350","article-title":"Keynote 057: phase II trial of pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin (BCG)","volume":"37","author":"Balar","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0049","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/jnci\/95.8.588","article-title":"Adherence to surveillance among patients with superficial bladder cancer","volume":"95","author":"Schrag","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00345-007-0223-2","article-title":"Screening for bladder cancer: a perspective","volume":"26","author":"Lotan","year":"2008","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2020.06.013_bib0051","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2013.06.010","article-title":"Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature","volume":"65","author":"Crivelli","year":"2014","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920302817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920302817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:19:51Z","timestamp":1761041991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920302817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1078143920302817"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.013","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}